U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15NO2.BrH
Molecular Weight 262.144
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DMPEA HYDROBROMIDE

SMILES

Br.COC1=CC=C(CCN)C=C1OC

InChI

InChIKey=HKJSUKPBCYPOJO-UHFFFAOYSA-N
InChI=1S/C10H15NO2.BrH/c1-12-9-4-3-8(5-6-11)7-10(9)13-2;/h3-4,7H,5-6,11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H15NO2
Molecular Weight 181.2316
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Homoveratrylamine (3,4-dimethoxyphenethylamine, DMPEA) is an analog of the major neurotransmitter dopamine where 3- and 4- position hydroxyl groups are replaced with methoxy groups. DMPEA is a metabolite of dopamine and is reported to be produced at elevated levels in patients with schizophrenia and Parkinson's disease. DMPEA inhibited monoamine oxidase and demonstrated no peripheral and central antidopaminergic activity in vivo.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Selective electrochemical discrimination between dopamine and phenethylamine-derived psychotropic drugs using electrodes modified with an acyclic receptor containing two terminal 3-alkoxy-5-nitroindazole rings.
2010-06
(E)-N-(3,4-Dimethoxy-pheneth-yl)-3-methoxy-but-2-enamide.
2010-01-23
An overview of Indian research in schizophrenia.
2010-01
Enhancement of 5-aminopenta-2,4-dienals electrophilicity via activation by O,N-bistrifluoroacetylation. application to an N-acyl Pictet-Spengler reaction.
2009-12-18
Self-assembly of 3,5-bis(ethoxycarbonyl)pyrazolate anions and ammonium cations of beta-phenylethylamine or homoveratrylamine into hetero-double-stranded helical structures.
2009-08-21
2-(4-Chloro-phen-yl)-5-(3,4-dimethoxy-pheneth-yl)-6,7-dihydro-pyrazolo[1,5-a]pyrazin-4(5H)-one.
2009-06-06
Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).
2009-03
4-[2-(3,4-Dimethoxy-phenethyl-amino)prop-oxy]-2-methoxy-benzamide.
2008-05-24
Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
2007-12
The structure of ammonium pyrazolates in the solid state.
2006-12
[Syntheses and ring-closures of difunctional tetrahydroisoquinolines].
2006
Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig liver slices.
2006
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
2004-11
Kinetics study of amine cleavage reactions of various resin-bound thiophenol esters from marshall linker.
2002-07-09
Fine structural specificity differences of trimethoprim allergenic determinants.
1996-10
3,4-dimethoxyphenethylamine (DMPEA) and schizophrenia.
1979-02
Patents

Sample Use Guides

In Vivo Use Guide
In vivo experiments with DMPEA were performed on mice. Compound was administered intraperitoneally at doses 25-200 mg/kg.
Route of Administration: Intraperitoneal
Brain mitochondria, containing monoamine oxidase, were prepared from Wistar female rats. Monoamine oxidase activity was determined in the presence and absence of the DMPEA by manometric technique. The main compartment of Warburg flasks contained 0.8 ml of a 0.1 M buffered solution of the homoveratrylamine, 1 ml of mitochondrial suspension (representing 500 mg wet weight of original brain tissue), and sufficient 0.01 M phosphate buffer (pH 7.4) to make a total volume of 2.7 ml. All aliquots for a given run were taken from the same mitochondrial preparation. The side arm of each flask contained 0.3 ml of 0.1 M tyramine or tryptamine hydrochloride. After the flasks were allowed to equilibrate for 15 min at 37°, the manometer valves were closed and the side arm contents of each were tipped in. Manometers were set at 150 mm, and readings were taken at 15-min intervals for 90 min. Values for the 90-min reaction period were obtained for each flask and were multiplied by the respective flask constants after adjusting for changes in the thermobarometer. The total microliters of oxygen uptake for each flask was thus obtained.
Substance Class Chemical
Created
by admin
on Wed Apr 02 15:02:05 GMT 2025
Edited
by admin
on Wed Apr 02 15:02:05 GMT 2025
Record UNII
ZZB3NR8KVD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DMPEA HYDROBROMIDE
Common Name English
Homoveratrylamine hydrobromide
Preferred Name English
3,4-Dimethoxy-phenethylamine hydrobromide
Systematic Name English
Benzeneethanamine, 3,4-dimethoxy-, hydrobromide (1:1)
Systematic Name English
Code System Code Type Description
CAS
54373-56-7
Created by admin on Wed Apr 02 15:02:05 GMT 2025 , Edited by admin on Wed Apr 02 15:02:05 GMT 2025
PRIMARY
FDA UNII
ZZB3NR8KVD
Created by admin on Wed Apr 02 15:02:05 GMT 2025 , Edited by admin on Wed Apr 02 15:02:05 GMT 2025
PRIMARY
PUBCHEM
20337306
Created by admin on Wed Apr 02 15:02:05 GMT 2025 , Edited by admin on Wed Apr 02 15:02:05 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE